MTZPY - Mitsubishi Tanabe Pharma Corporation

Other OTC - Other OTC Delayed Price. Currency in USD

Mitsubishi Tanabe Pharma Corporation

3-2-10, Dosho-machi
Chuo-ku
Osaka 541-8505
Japan
81 6 6205 5211
http://www.mt-pharma.co.jp

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees7,228

Key executives

NameTitlePayExercisedYear born
Mr. Masayuki MitsukaMember of the BoardN/AN/A1954
Mr. Hiroaki UenoPres & Representative DirectorN/AN/A1958
Megumi OhtakiExec. Officer & Chief Compliance OfficerN/AN/AN/A
Yoshiaki TakaiVP & Head of Corp. Communications DepartmentN/AN/AN/A
Yasutoshi KawakamiExec. Officer and Head of Sale & Marketing DivisionN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan, Europe, North America, other Asian countries, and internationally. The company primarily offers drugs for immuno-inflammation, diabetes and kidney, and central nervous system diseases; vaccines; and OTC products. It offers Simponi, a treatment agent for rheumatoid arthritis (RA); Canalia, Invokana, Tenelia, and Canaglu, treatment agents for type 2 diabetes mellitus; Stelara and Amiselimod for treatment of Crohn's disease; Radicava, an amyotrophic lateral sclerosis (ALS) treatment agent; Gilenya, a treatment agent for multiple sclerosis; and Remicade for treatment of RA, Crohn's disease, and various inflammatory autoimmune diseases. The company also provides Lexapro, an anti-depressant agent; Imusera for multiple sclerosis; Rupafin, an oral allergy treatment agent; Talion, an anti-allergic agent; Fasinumab, a human anti-NGF monoclonal antibody; Dersimelagon for immnuno-inflammation; Vadadustat, for treatment of renal anemia; and Apararenone, for treatment of non-alcoholic steatohepatitis. In addition, it offers vaccines, such as influenza vaccine, Tetrabik, Mearubik, Varicella vaccine, and JEBIK V. The company has collaborations with Dyadic International, Inc.; Hitachi Ltd.; HitGen Ltd.; and Viela Bio, Inc. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

Corporate governance

Mitsubishi Tanabe Pharma Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.